The activation and proliferation of microglia is characteristic of the early stages of brain pathologies. In this study, we aimed to identify a factor that promotes microglial activation and proliferation and examined the in vitro effects on these processes. We cultured microglial cell lines, EOC 2 and SIM-A9, with various growth factors and evaluated cell proliferation, death, and viability. The results showed that only transforming growth factor beta (TGF-β) caused an increase in the in vitro proliferation of both microglial cell lines. It has been reported that colony-stimulating factor 1 promotes the proliferation of microglia, while TGF-β promotes both proliferation and inhibition of cell death of microglia. However, upon comparing the most effective doses of both (assessed from the proliferation assay), we identified no statistically significant difference between the two factors in terms of cell death; thus, both have a proliferative effect on microglial cells. In addition, a TGF-β receptor 1 inhibitor, galunisertib, caused marked inhibition of proliferation in a dose-dependent manner, indicating that inhibition of TGF-β signalling reduces the proliferation of microglia. Therefore, galunisertib may represent a promising therapeutic agent for the treatment of neurodegenerative diseases via inhibition of nerve injury-induced microglial proliferation, which may result in reduced inflammatory and neuropathic and cancer pain.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016844 | PMC |
http://dx.doi.org/10.3390/brainsci10010020 | DOI Listing |
Neuroscience
January 2025
Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, Guangzhou 510080, China. Electronic address:
Acute peripheral vestibular dysfunction is associated with a variety of postural and balance disturbances. Vestibular rehabilitation training (VRT) is widely acknowledged as an effective intervention for promoting vestibular compensation. Nevertheless, the broader implementation of early VRT is hindered by an incomplete understanding of its neurobiological mechanisms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Los Angeles, Los Angeles, CA, USA.
Background: Alzheimer's Disease and other neurodegenerative diseases are characterized by abnormal tau protein accumulation in the brain. PET imaging utilizing the [F-18]flortaucipir tracer is a widely used method for visualizing such conditions, yet its effectiveness can be compromised by off-target binding. To shed light on this issue, our study focuses on how elevated cholesterol concentrations of low-density lipoproteins (LDL) and standard uptake values (SUVR) from corresponding tau-PET scans may influence the efficacy of [F-18]flortaucipir.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Riverside, Riverside, CA, USA.
Background: Alzheimer's Disease (AD) is characterized by the accumulation of beta-amyloid plaques and tau protein tangles and neurodegeneration, with growing interest in the role of neuroinflammation. The neuroinflammatory response to an insult is modulated by microglia, which transition from a resting state marked by ramified, branching processes to an activated stated in which they proliferate, migrate, and swell (processes shorten, somas enlarge). Animal studies have shown that diffusion-weighted magnetic resonance imaging (MRI) is sensitive to these morphological differences in microglia, with higher diffusion in brain regions experiencing inflammation.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is characterized by the extracellular accumulation of senile plaques composed of beta-amyloid (Aβ) and the intracellular deposition of neurofibrillary tangles composed of hyperphosphorylated tau (Tp). Aβ induces a chronic neuroinflammation that contributes to the neurite network disorganization and finally neuronal death. Lecanemab, a humanized monoclonal antibody (Ab) that recognizes protofibrils/oligomers and prevents Aβ deposition, is the first US approved Ab for AD.
View Article and Find Full Text PDFBackground: PLCG2 is signal-transduction protein identified as a potential drug target for the treatment of Alzheimer's disease (AD). PLCG2 is regulated by stimulation of the TREM2 pathway in microglia, which results in phagocytosis of beta-amyloid. PLCG2 catalyzes the cleavage of PI(4,5)P2 into IP3 and diacylglycerol, resulting in increased cell motility, phagocytosis, and proliferation in microglia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!